Access to general practitioners in South Australia: a population survey

OBJECTIVE: To determine the timeliness of access to general practitioner appointments in South Australia. DESIGN AND SETTING: Face-to-face interviews with a random and representative sample of South Australians living in metropolitan Adelaide and country towns with a population of 1000 or more in 2007. PARTICIPANTS: 2507 people aged 15 years and over who had seen a GP in the previous 12 months. MAIN OUTCOME MEASURES: Waiting times for obtaining an appointment with a GP, patients’ perceptions about appointment waiting times, and waiting times at the GP’s surgery. RESULTS: Most respondents reported that for their last visit with a GP, they were able to be seen on the same day (39%) or within 1 or 2 working days (33%); 20% waited more than 2 working days for their appointment. Nine per cent of respondents (159/1764) reported waiting more than 2 working days because an earlier appointment was not available. Respondents reporting lower levels of household income were more likely to report longer waits for GP appointments. Most respondents (78%) felt that they were able to make a GP appointment as soon as they thought necessary. At the surgery, 46% of respondents were seen within 15 minutes, but 13% waited 45 minutes or longer. CONCLUSIONS: In general, access to GPs is timely, and most South Australians reported that for their last GP visit they were able to make an appointment as soon as they thought was necessary.Richard L. Reed, Leigh S. Roeger, Nova Reinfeld-Kirkman and Sara L. Howar

Epic battles of the chessboard /

Includes index.Published in London in 1948 under title: Battles-royal of the chessboard.Mode of access: Internet

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).

Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4-5 December, 2019, Naples, Italy), and are summarised in this report